These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 7687728

  • 21. Infarct size limitation by a new Na(+)-H+ exchange inhibitor, Hoe 642: difference from preconditioning in the role of protein kinase C.
    Miura T, Ogawa T, Suzuki K, Goto M, Shimamoto K.
    J Am Coll Cardiol; 1997 Mar 01; 29(3):693-701. PubMed ID: 9060913
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
    Linz W, Schölkens BA, Kaiser J, Just M, Qi BY, Albus U, Petry P.
    Cardiovasc Drugs Ther; 1989 Dec 01; 3(6):873-82. PubMed ID: 2535056
    [Abstract] [Full Text] [Related]

  • 27. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
    Komers R, Cooper ME.
    Am J Physiol; 1995 Apr 01; 268(4 Pt 2):F588-94. PubMed ID: 7733315
    [Abstract] [Full Text] [Related]

  • 28. Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model.
    Kobara M, Tatsumi T, Kambayashi D, Mano A, Yamanaka S, Shiraishi J, Keira N, Matoba S, Asayama J, Fushiki S, Nakagawa M.
    J Cardiovasc Pharmacol; 2003 Jun 01; 41(6):880-9. PubMed ID: 12775965
    [Abstract] [Full Text] [Related]

  • 29. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries.
    Sudhir K, Chou TM, Hutchison SJ, Chatterjee K.
    Circulation; 1996 May 01; 93(9):1734-9. PubMed ID: 8653880
    [Abstract] [Full Text] [Related]

  • 30. Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: involvement of bradykinin, protein kinase C and prostaglandins.
    Jin ZQ, Chen X.
    Clin Exp Pharmacol Physiol; 2000 Apr 01; 27(4):257-62. PubMed ID: 10779122
    [Abstract] [Full Text] [Related]

  • 31. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.
    Hecker M, Pörsti I, Bara AT, Busse R.
    Br J Pharmacol; 1994 Jan 01; 111(1):238-44. PubMed ID: 8012702
    [Abstract] [Full Text] [Related]

  • 32. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W, Schölkens BA.
    J Cardiovasc Pharmacol; 1992 Jan 01; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart.
    Kositprapa C, Ockaili RA, Kukreja RC.
    J Mol Cell Cardiol; 2001 Jul 01; 33(7):1355-62. PubMed ID: 11437541
    [Abstract] [Full Text] [Related]

  • 35. Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat.
    Rose J, Ehring T, Sakka SG, Skyschally A, Heusch G.
    J Mol Cell Cardiol; 1996 Mar 01; 28(3):603-13. PubMed ID: 9011643
    [Abstract] [Full Text] [Related]

  • 36. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo.
    Sun W, Wainwright CL.
    Coron Artery Dis; 1994 Jun 01; 5(6):541-50. PubMed ID: 7952414
    [Abstract] [Full Text] [Related]

  • 37. Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
    Richardt D, Wolfrum S, Büttner C, Schäfer U, Dendorfer A, Kurz T, Richardt G.
    J Cardiovasc Pharmacol; 2002 Oct 01; 40(4):641-6. PubMed ID: 12352328
    [Abstract] [Full Text] [Related]

  • 38. Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.
    Veeravalli KK, Akula A, Routhu KV, Kota MK.
    Pharmacol Res; 2003 Dec 01; 48(6):557-63. PubMed ID: 14527819
    [Abstract] [Full Text] [Related]

  • 39. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.
    McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN.
    Circulation; 1995 Apr 01; 91(7):2043-8. PubMed ID: 7895363
    [Abstract] [Full Text] [Related]

  • 40. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat.
    Massoudy P, Becker BF, Gerlach E.
    J Cardiovasc Pharmacol; 1994 Apr 01; 23(4):632-9. PubMed ID: 7516015
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.